TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement in autonomic function indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hearing improvement at high frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total gastric volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: hospital-free days
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: major adverse kidney events within 30 days
Endpoint domain: Adverse events/effects
Endpoint subdomain: null
Primary endpoint: Degree of granulation and crusting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding during nasal packing removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PND frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hoarseness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chronic cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint inflammation measured by radioleucoscintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-day clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of nasal congestion/runny nose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence from day care
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: mean total severity per day in reported episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step Up/Over test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of sentinel lymph nodes (SLNs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratings of 'stimulated'
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ratings of 'like cocaine'
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ratings of 'likely to use cocaine if had access'
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in DALLAS scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain experienced fell by 24%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PNAC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in skeletal-related events (SREs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in skeletal morbidity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Dietary Questionnaire score for fruit and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satiety responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Submission of stimulant‐ and alcohol‐negative samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving continuous abstinence for 4, 8, and 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Variability (RV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total symptom score over 10 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV and RV systolic velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High-quality oocyte rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: High-quality embryo rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Plasma levels of proinflammatory molecules (TNF and leptin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma levels of antiinflammatory molecules (adiponectin and IL-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma insulin and HOMA-IR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: satisfaction difference between groups
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of gynaecological infection
Endpoint domain: Adverse events/effects
Primary endpoint: Net societal cost per woman
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Cost-effectiveness of management methods
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Peak cortisol levels following ACTH stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: subjective arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaginal pulse amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suture expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: De-Qi scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCD symptoms measured by Y-BOCS-OR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3 and 5 year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Days without immunization coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of well-child visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGA ratings of 'good' or 'excellent'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall ease-of-care ratings
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Safety and tolerability of felodipine
Endpoint domain: Adverse events/effects
Primary endpoint: Diminution of sovrafascial edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of steps at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of ICU stay days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of correctly recognized words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graft survival at 1 and 2.5 years
Endpoint domain: Mortality/survival
Primary endpoint: acute cellular rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Lower heart rates at submaximal workloads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxygen uptake at submaximal workloads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic blood pressure at submaximal workloads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GIP-induced insulin secretion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Need for glucose maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bishop score >6 at time of catheter removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision-related quality of life composite score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Shear punch strengths of resin-containing luting cements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of intercourse attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with sildenafil
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patients stopping BCG due to side effects
Endpoint domain: Adverse events/effects
Primary endpoint: earlier relapse in patients treated with interferon alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCORAD reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pruritus index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall global assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: In-hospital cardiogenic shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating cytokines levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of uncovered struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of IS-Th
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of IRP
Endpoint domain: Adverse events/effects
Primary endpoint: HAM-D17 total scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late lumen loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: No residual edema (CRT <300 μm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients reaching blood pressure target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean reduction of systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean reduction of diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rose Bengal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear break up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of PICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Peripheral sensory neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Isovolumetric detrusor pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: QT interval shortening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: vocal efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vocal fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: fatigue-inertia mood state
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: improvement in GMFM scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: independent walking cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orthodontic bracket bond strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FBG, HbA1c and HOMA‐IR value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglycerides and total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of PRBC transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contractile index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cortisol response to citalopram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prolactin response to citalopram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in aqueous humor flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in color of peri-implant mucosa compared to gingiva (Δa*)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Child-Turcotte-Pugh (CTP) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed nausea of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Use of antiemetic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: present pain intensity (PPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Within-visit RAL agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean differences of within-visit RAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard deviations of differences in RAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Access site hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: health promoting behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Laser fluorescence measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC of dihydroartemisinin and desethylamodiaquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of wake/sleep bouts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep bout duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of wake bouts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the numbers and proportions of red complex bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: immediate improvement in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immediate improvement in mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for intravenous fluid therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hospital admission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Functionally active CACs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: freedom from AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: post-Fontan catheter interventions
Endpoint domain: Adverse events/effects
Primary endpoint: Overall remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ≥50% reduction on the HAM-D score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission (HAM-D score ≤ 7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of perceived pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in motor performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid volume SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Functional outcomes (Glasgow Outcome Scale or Barthel index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total RMST (Restricted Mean Survival Time)
Endpoint domain: Mortality/survival
Primary endpoint: Increased intent to complete an AD
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Increased knowledge on AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reaction times after fluid loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clot formation times after fluid loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cholesterol management improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood βHB concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean itch severity score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum creatine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic external root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: plasma iPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: narcotic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unscheduled visits to healthcare facilities
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: rate of adverse events or complications
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative PCA consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wheezing episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recurrence rate of wheezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite of death from cardiovascular causes, myocardial infarction, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Rates of moderate and severe bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of intracranial hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in peripheral endothelial progenitor cells (EPCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Better visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual field improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in central nocturnal SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of sore throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MBI score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell apoptosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response criteria for rheumatoid arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Arterial Pressure (MAP) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of social behaviour
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: food-related behaviour
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Effectiveness of IPT-G for the treatment of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Alphabeta(40) in plasma and cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBsAg clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: renal function parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduced systolic and diastolic myocardial reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: prevalence of bothersome symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Nasal obstruction relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per life gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in CL(cortisol‐‐>6beta‐hydroxycortisol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decrease in urinary 6beta‐hydroxycortisol/cortisol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean plasma lansoprazole levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of new vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cumulative incidence of nonvertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Collagen type 1 cross-linked C-telopeptide (CTX) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adrenocorticotropic hormone (ACTH) suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of radiation-induced skin toxicity
Endpoint domain: Adverse events/effects